Cleveland BioLabs and Incuron Announce US and European Patent Allowances for Curaxins

Cleveland BioLabs and Incuron Announce US and European Patent Allowances for

BUFFALO, N.Y., May 14, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc.
(Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and
Bioprocess Capital Ventures, today announced the receipt of a Notice of
Allowance from the U.S. Patent and Trademark Office for the Curaxin U.S.
Patent Application Number 12/993,018, titled "Inducing Cell Death by
Inhibiting Adaptive Heat Shock Response." This patent was recently issued in
the Russian Federation, as well. Curaxins include CBL0137, which is a
carbazole and CBL0102, which is a quinacrine.

The European Patent Office also issued a Notice of Grant for European Patent
Number EP2356093, titled "Carbazole Compounds and Therapeutic Uses of the
Compounds." This patent was also allowed in New Zealand, South Africa, and

In addition, the Australian patent authority had previously granted patent
Number 2005267117 titled, "Inhibition of NF-kappaB" for carbazole compounds.

Andrei Gudkov, Ph.D., D.Sci., Chief Scientific Officer of Cleveland BioLabs,
noted, "Inhibition of adaptive heat shock response and NF-kappaB have long
been recognized as attractive targets for oncology therapeutics. In fact, many
known efficacious drugs being used today focus on these targets independently,
which underscores the importance of these patents. The uniqueness of our
Curaxin drug candidates CBL0137 and CBL0102 is that they simultaneously affect
both of these pathways and others through interaction with an upstream
regulator. As such, we hope our Curaxins will provide a clinically relevant
improvement to existing therapies."

CBLI and Incuron recently announced the receipt of a Notice of Allowance from
the U.S. Food and Drug Administration (FDA) for an Investigational New Drug
(IND) application for CBL0137.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging
deep mechanistic understanding of the cell death process, apoptosis, to
develop a robust pipeline of compounds primarily focused on oncology
applications and mitigation of radiation injury. The Company's lead compound
is being developed as both a radiation countermeasure and a cancer treatment.
The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs,
Inc., and strategic relationships with the Cleveland Clinic, Roswell Park
Cancer Institute, the Children's Cancer Institute Australia and the Armed
Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs,
Inc., please visit the Company's website at

About Incuron, LLC

Incuron, LLC is a Russian Federation based joint venture founded in 2010
between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and
Cleveland BioLabs. Incuron is developing CBL0102 and CBL0137 for oncology and
orphan indications. To learn more about Incuron, LLC, please visit the
company's website at

This press release contains certain forward-looking information about
Cleveland BioLabs that is intended to be covered by the safe harbor for
"forward-looking statements" provided by the Private Securities Litigation
Reform Act of 1995, as amended. Forward-looking statements are statements that
are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"
"will," "may," "anticipate(s)" and similar expressions are intended to
identify forward-looking statements. These statements include, but are not
limited to, statements regarding our ability to successfully obtain regulatory
approval for our therapeutic product candidates; statements regarding our
ability to successfully develop and commercialize our therapeutic products;
our ability to expand our long-term business opportunities; the conduct and
results of our various clinical trials; and future performance. All of such
statements are subject to certain risks and uncertainties, many of which are
difficult to predict and generally beyond the control of the Company, that
could cause actual results to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements.

These factors include, among others, the Company's inability to obtain
regulatory approval in a timely manner or at all; the Company's failure to
develop new products; the Company's collaborative relationships and the
financial risks related thereto; the risks inherent in the early stages of
drug development and in conducting clinical trials. Some of these factors
could cause future results to materially differ from the recent results or
those projected in forward-looking statements.See also the "Risk Factors" and
"Forward-Looking Statements" described in the Company's periodic filings with
the Securities and Exchange Commission.

Rachel Levine, Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439

Cleveland BioLabs, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.